Di Leo, A <br/><br/>
Epirubicin plus medroxyprogesterone as second-line treatment of advanced prostatic cancer. A study by the Italian Trials in Medical Oncology Group.  [electronic resource] 

 -  American journal of clinical oncology  Jun 1995 
 - 239-44 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>0277-3732 
<br/><br/><label>Standard No.: </label>10.1097/00000421-199506000-00011  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Ambulatory Care<br/>Bone Neoplasms--drug therapy<br/>Drug Synergism<br/>Drug Therapy, Combination<br/>Epirubicin--administration & dosage<br/>Heart Failure--chemically induced<br/>Humans<br/>Male<br/>Medroxyprogesterone Acetate--administration & dosage<br/>Middle Aged<br/>Neoplasms, Hormone-Dependent--drug therapy<br/>Pain--drug therapy<br/>Pain Measurement<br/>Palliative Care<br/>Prostatic Neoplasms--drug therapy<br/>Survival Analysis